Develops devices that ablate heart tissue to treat atrial fibrillation.
Jun 2026Revenue $1.19M/yrExpenses $84.2M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Pulse Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.19M and expenses $84.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $350K | $77.3M | −$76.9M |
| Dec 2024 | $0.00 | $56.3M | −$56.3M |
| Dec 2023 | $0.00 | $43.6M | −$43.6M |
| Dec 2022 | $700K | $58.8M | −$58.1M |
| Dec 2021 | $1.42M | $64.4M | −$63.0M |
| Dec 2020 | $0.00 | $50.0M | −$50.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.